Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical Co Ltd (TAK) officer Andrew Stewart Plump gave notice of a proposed sale of 116,191 common shares from the Andrew S Plump 2020 Rev Trust U/A 12/2/20. The shares have an aggregate market value of $2,148,372.09, with an approximate sale date of September 2, 2026.
The shares are identified as RSUs and PSUs acquired from the issuer on August 20, 2020. The notice lists a prior sale of 19,651 common shares on August 19, 2026, for gross proceeds of $363,348.49. May 15, 2026 is listed as the plan-adoption or instruction date for reliance on Rule 10b5-1.
Takeda Pharmaceutical Company Limited (TAK) reports that the U.S. FDA has approved MIMRYLO (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera, a chronic blood cancer. MIMRYLO is a first-in-class subcutaneous hepcidin mimetic designed to regulate iron distribution and reduce excess red blood cell production to maintain hematocrit control, the primary treatment goal in PV.
The approval is based on the global Phase 3 VERIFY study in 293 patients, where 76.9% of patients achieved clinical response during Weeks 20–32 and the drug met all efficacy endpoints, including hematocrit control, reduced phlebotomy need and improved fatigue, with a generally favorable safety profile. Common adverse reactions included injection site reactions (56%) and anemia (16%). The company states that this U.S. approval does not change its consolidated financial forecast for the fiscal year ending March 31, 2027, and highlights MIMRYLO as part of three new medicines expected to support future growth.
TAKEDA PHARMACEUTICAL CO LTD (TAK) director and officer Andrew Stewart Plump, President, R&D, reported the sale of 19,651 American Depositary Shares of Takeda on August 19, 2026 at $18.49 per ADS. The shares were held indirectly by a trust, which held 261,656 ADS afterward. Separately, Plump reported 766,569 ADS held directly following the reported transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on May 15, 2026.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported an insider share sale by Chief Human Resources Officer Nicola Deidre Petal Greenway. On 2026-08-18, she sold 12,980 American Depositary Shares at $18.1139 per share in an open market or private transaction, and 40,049 ADS remain held directly.
TAKEDA PHARMACEUTICAL CO LTD (TAK) received a Rule 144 notice covering a planned sale of common stock beneficially owned for the account of officer Andrew Stewart Plump. The filing indicates plans to sell 19,651 shares of TAK common stock through Fidelity Brokerage Services LLC on or about August 19, 2026 on the NYSE.
The shares to be sold were acquired from the issuer on August 20, 2020 as RSU's and PSU's and are held in the ANDREW S PLUMP 2020 REV TR U/A 12/2/20. The filing lists an aggregate market value of $363,348.49 for the proposed sale and shows 1,579,836,830 shares outstanding of TAK common stock as context.
Nicola Greenway filed a notice to sell 12,980 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Limited through Interactive Brokers LLC on August 14, 2026 on the NYSE. The ADSs derive from Restricted Stock Unit Awards – Vested as of July 31, 2026.
The filing also lists prior sales over the past three months, including 6,774 ADSs for $115,835.40 and 34,603 ADSs for $605,552.50, both dated August 10, 2026.
Takeda Pharmaceutical Co. Ltd. reports that Chief Medical Officer Farajallah Awny Samaan Botros sold 14,006 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction represents a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, Botros directly holds 116,177 American Depositary Shares.
Takeda Pharmaceutical Co Ltd executive Ramy Riad Ahmed, President of the PDT business unit, reported a sale of 7,277 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. A footnote states this was a mandatory sale to cover taxes related to the vesting of equity awards. Following this transaction, Ahmed directly holds 102,588 American Depositary Shares.
Takeda Pharmaceutical Co Ltd executive Rhonda Janice Pacheco, President, U.S. Business Unit, reported the sale of 16,901 American Depositary Shares on 2026-08-10. The transaction was a mandatory sale to cover taxes triggered by vesting of equity awards, executed at a $17.10 weighted average price per ADS. Following this tax-related sale, she directly holds 182,507 ADS.
TAKEDA PHARMACEUTICAL CO LTD executive Lauren Rusckowski Duprey, Chief Transformation Officer, reported selling 47,586 American Depositary Shares on 2026-08-10. The sale was described as a mandatory sale to cover taxes associated with vesting of equity awards. The reported $17.10 figure is a weighted average price for the transaction. After this sale, Duprey directly held 226,057 American Depositary Shares.